公开(公告)号：US5457529A

公开(公告)日：1995-10-10

申请号：US271447

申请日：1994-07-07

申请人： Volker Tank ,  Peter Haschberger ,  Burkhard Jansen ,  Erwin Lindermeir ,  Klaus Scheider

发明人： Volker Tank ,  Peter Haschberger ,  Burkhard Jansen ,  Erwin Lindermeir ,  Klaus Scheider

IPC分类号： G01B9/02 ,  G01J3/453 ,  G01J9/02

CPC分类号： G01J9/02 ,  G01J3/4532

摘要： In a Michelson interferometer, two plane mirrors of the mirror unit (50) are embodied as two plane mirrors (51, 52) of different sizes, disposed eccentrically and parallel to one another. A hollow shaft (63), rotatably supported in a bearing block (62) and driven by a drive unit (65), is also provided, which is disposed between a beam splitter and the mirror unit (50) and whose axis of rotation (61) coincides with the axis of rotation of the mirror unit (50). The mirror unit (50) is secured to the hollow shaft (63) in such a way that the axis of rotation (61) of the hollow shaft passes through the mirror face of the smaller plane mirror (51), whose axis of rotation forms an acute angle (.beta.) with the vertical to the smaller plane mirror (51), so that the two beams formed at the beam splitter (1) pass, via the tilted mirrors, through the hollow shaft (63) to strike the centrally disposed mirror face of the smaller plane mirror ( 51), are reflected by it to the opposite mirror face of the larger plane mirror (52) and from there to two stationary plane mirrors (71, 72) in such a way that they strike the stationary plane mirrors (71, 72) vertically, and--reflected by those mirrors--take the same path in the opposite direction, recombine at the beam splitter, and are focused by means of an optical element onto a detector (4).

摘要翻译： 在迈克尔逊干涉仪中，反射镜单元（50）的两个平面镜被实施为彼此偏心并平行设置的不同尺寸的两个平面镜（51,52）。 还设置有可旋转地支撑在轴承座（62）中并由驱动单元（65）驱动的中空轴（63），其设置在分束器和反射镜单元（50）之间并且其旋转轴线 61）与镜单元（50）的旋转轴线重合。 镜单元（50）以空心轴的旋转轴线（61）穿过其平面反射镜（51）的镜面（其旋转轴线形成）的方式固定到中空轴 与较小的平面镜（51）垂直的锐角（β），使得形成在分束器（1）处的两个光束经由倾斜反射镜通过空心轴（63）以撞击中心设置 较小的平面镜（51）的镜面被其反射到较大的平面镜（52）的相对的镜面，并从那里反射到两个固定平面镜（71,72），使得它们撞击静止 由这些反射镜垂直和反射的平面镜（71,72）沿相反方向取相同的路径，在分束器处复合，并通过光学元件聚焦到检测器（4）上。

公开(公告)号：US5341207A

公开(公告)日：1994-08-23

申请号：US926618

申请日：1992-08-10

申请人： Volker Tank ,  Peter Haschberger ,  Burkhard Jansen

发明人： Volker Tank ,  Peter Haschberger ,  Burkhard Jansen

IPC分类号： G01J3/45 ,  G01J3/06 ,  G01J3/453 ,  G01B9/02

CPC分类号： G01J3/06 ,  G01J3/453

摘要： In each arm of a Michelson interferometer (IF) a retroreflector (110; 110') having its aperture plane aligned perpendicularly to the optical axis is mounted on a respective holder (106; 106') which in turn is rigidly connected to one end of a shaft (105; 105') rotatably mounted in a connecting member (103; 103'). To the other end of the shaft (105; 105') a first gear (107.sub.1 ; 107.sub.1 ') is secured which is coupled via a toothed belt (909; 109') to an identically configured second gear (107.sub.2 ; 107.sub.2 ') which concentrically to a drive shaft (102; 102') of an electric motor (101; 101') is rigidly connected to the housing (1010; 1010') thereof. At a predetermined distance from the shaft (105; 105') the drive shaft (102; 102') is fixedly connected to the connecting member (103; 103') so that on rotation of the motor drive shafts (102; 102') the length of the optical paths is shortened in one interferometer arm and lengthened synchronously therewith in the other interferometer arm, or vice versa. Furthermore, the aperture planes of the two retroreflectors (110, 110') always remain unchanged aligned perpendicularly to the optical axis (FIG. 2 ).

摘要翻译： 在迈克尔逊干涉仪（IF）的每个臂中，具有其垂直于光轴对准的孔径平面的后向反射器（110; 110'）安装在相应的保持器（106; 106'）上，该保持器又与 可旋转地安装在连接构件（103; 103'）中的轴（105; 105'）。 固定在轴（105; 105'）的另一端，第一齿轮（1071; 1071'）经由齿形带（909; 109'）连接到相同配置的第二齿轮（1072; 1072'）上， 与电动机（101; 101'）的驱动轴（102; 102'）同心地刚性连接到其壳体（1010; 1010'）。 在与轴（105; 105'）预定的距离处，驱动轴（102; 102'）固定地连接到连接构件（103; 103'），使得在马达驱动轴（102; 102'）的旋转时， 在另一个干涉仪臂中，一个干涉仪臂中的光路的长度被缩短并与其同步地延长，反之亦然。 此外，两个后向反射器（110,110'）的孔径平面保持不变地垂直于光轴对齐（图2）。

公开(公告)号：US08759308B2

公开(公告)日：2014-06-24

申请号：US12845521

申请日：2010-07-28

申请人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

发明人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

IPC分类号： A61K48/00

CPC分类号： C12N15/113 ,  A61K31/712 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

摘要： RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

摘要翻译： 可用作治疗各种类型癌症的RNAi序列，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大细胞淋巴瘤和黑素瘤 ; 和阿尔茨海默病。 这些序列同时靶向簇蛋白，IGFBP-5，IGFBP-2，IGFBP-2和-5两者，Mitf和B-raf。 本发明进一步提供这些RNAi序列用于治疗各种类型的癌症，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大 细胞淋巴瘤和黑素瘤; 和阿尔茨海默病，以及通过向包括需要这种治疗的人的个体的个体施用具有RNAi活性的RNA分子来治疗这些病症的方法。

公开(公告)号：US20120202873A1

公开(公告)日：2012-08-09

申请号：US13404741

申请日：2012-02-24

申请人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P. Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

发明人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P. Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

IPC分类号： C07H21/02 ,  A61P35/04 ,  A61K31/7105

CPC分类号： C12N15/113 ,  A61K31/712 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

摘要： RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

摘要翻译： 可用作治疗各种类型癌症的RNAi序列，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大细胞淋巴瘤和黑素瘤 ; 和阿尔茨海默病。 这些序列同时靶向簇蛋白，IGFBP-5，IGFBP-2，IGFBP-2和-5两者，Mitf和B-raf。 本发明进一步提供这些RNAi序列用于治疗各种类型的癌症，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大 细胞淋巴瘤和黑素瘤; 和阿尔茨海默病，以及通过向包括需要这种治疗的人的个体的个体施用具有RNAi活性的RNA分子来治疗这些病症的方法。

公开(公告)号：US20110034473A1

公开(公告)日：2011-02-10

申请号：US12937245

申请日：2009-04-08

申请人： Victor J. Bauer ,  Mike H. O'Neill ,  Barbara J. Kidon ,  Burkhard Jansen

发明人： Victor J. Bauer ,  Mike H. O'Neill ,  Barbara J. Kidon ,  Burkhard Jansen

IPC分类号： A61K31/4985 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

CPC分类号： C07D487/04

摘要： A novel co-crystal of N′-(7-fluoropyrrolo[1,2a]quinoxalin-4-yl)pyrazine-2-carbohydrazide with oxalic acid is disclosed. The disclosed oxalic acid co-crystal demonstrates cancer cell growth inhibition and is more bioavailable than the corresponding free base when administered as a suspension.

摘要翻译： 公开了N' - （7-氟吡咯并[1,2a]喹喔啉-4-基）吡嗪-2-碳酰肼与草酸的新型共晶体。 所公开的草酸共晶体表现为癌细胞生长抑制，并且当作为悬浮液施用时比相应的游离碱更具生物利用度。

公开(公告)号：US07820635B2

公开(公告)日：2010-10-26

申请号：US12116083

申请日：2008-05-06

申请人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

发明人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

IPC分类号： A61K48/00

CPC分类号： C12N15/113 ,  A61K31/712 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

摘要： RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

摘要翻译： 可用作治疗各种类型癌症的RNAi序列，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大细胞淋巴瘤和黑素瘤 ; 和阿尔茨海默病。 这些序列同时靶向簇蛋白，IGFBP-5，IGFBP-2，IGFBP-2和-5两者，Mitf和B-raf。 本发明进一步提供这些RNAi序列用于治疗各种类型的癌症，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大 细胞淋巴瘤和黑素瘤; 和阿尔茨海默病，以及通过向包括需要这种治疗的人的个体的个体施用具有RNAi活性的RNA分子来治疗这些病症的方法。

公开(公告)号：US07285541B2

公开(公告)日：2007-10-23

申请号：US10646391

申请日：2003-08-21

申请人： Martin Gleave ,  Burkhard Jansen

发明人： Martin Gleave ,  Burkhard Jansen

IPC分类号： A61K48/00 ,  C07H21/02 ,  C07H21/04

CPC分类号： C12N15/113 ,  A61K31/712 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

摘要： Treatment of melanoma is achieved through reduction in the effective amount of clusterin in melanoma cells of in a mammalian subject, preferably a human. A therapeutic agent effective to reduce the effective amount of clusterin in the melanoma cells is administered to the subject. The therapeutic agent may be, for example, an antisense ODN or small inhibitory RNA (siRNA) compound targeted to clusterin. bcl-xL in a subject or cell line can also be regulated by administering to the subject or cell line an agent effective to modulate the amount of clusterin expression. In particular, in clusterin expressing cells, the expression of bcl-xL is down-regulated when the effective amount of clusterin is reduced. Such inhibition is significant because bcl-xL is known to act as an inhibitor of apoptosis.

摘要翻译： 黑素瘤的治疗通过在哺乳动物受试者，优选人中减少黑素瘤细胞中的聚集蛋白的有效量来实现。 向受试者施用有效降低黑素瘤细胞中的聚集蛋白有效量的治疗剂。 治疗剂可以是例如靶向簇蛋白的反义ODN或小的抑制性RNA（siRNA）化合物。 受试者或细胞系中的bcl-xL也可以通过向受试者或细胞系施用有效调节聚集蛋白表达量的试剂来调节。 特别地，在簇蛋白表达细胞中，当有效量的聚集蛋白降低时，bcl-xL的表达下调。 这种抑制是显着的，因为已知bcl-xL作为凋亡抑制剂。

公开(公告)号：US09487777B2

公开(公告)日：2016-11-08

申请号：US13404741

申请日：2012-02-24

申请人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P. Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

发明人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P. Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

IPC分类号： C07H21/04 ,  C12N15/113 ,  A61K31/712 ,  A61K38/00

CPC分类号： C12N15/113 ,  A61K31/712 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

摘要： RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

摘要翻译： 可用作治疗各种类型癌症的RNAi序列，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大细胞淋巴瘤和黑素瘤 ; 和阿尔茨海默病。 这些序列同时靶向簇蛋白，IGFBP-5，IGFBP-2，IGFBP-2和-5两者，Mitf和B-raf。 本发明进一步提供这些RNAi序列用于治疗各种类型的癌症，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大 细胞淋巴瘤和黑素瘤; 和阿尔茨海默病，以及通过向包括需要这种治疗的人的个体的个体施用具有RNAi活性的RNA分子来治疗这些病症的方法。

公开(公告)号：US08058437B2

公开(公告)日：2011-11-15

申请号：US12937245

申请日：2009-04-08

申请人： Victor J Bauer ,  Mike H O'Neill ,  Barbara J Kidon ,  Burkhard Jansen

发明人： Victor J Bauer ,  Mike H O'Neill ,  Barbara J Kidon ,  Burkhard Jansen

IPC分类号： C07D241/42 ,  A61K31/498

CPC分类号： C07D487/04

摘要： A novel co-crystal of N′-(7-fluoropyrrolo[1,2a]quinoxalin-4-yl)pyrazine-2-carbohydrazide with oxalic acid is disclosed. The disclosed oxalic acid co-crystal demonstrates cancer cell growth inhibition and is more bioavailable than the corresponding free base when administered as a suspension.

摘要翻译： 公开了N' - （7-氟吡咯并[1,2a]喹喔啉-4-基）吡嗪-2-碳酰肼与草酸的新型共晶体。 所公开的草酸共晶体表现为癌细胞生长抑制，并且当作为悬浮液施用时比相应的游离碱更具生物利用度。

公开(公告)号：US07208270B2

公开(公告)日：2007-04-24

申请号：US10176372

申请日：2002-06-21

申请人： Burkhard Jansen ,  Trevor Lucas

发明人： Burkhard Jansen ,  Trevor Lucas

IPC分类号： C12Q1/68 ,  G01N33/53 ,  C12P19/34

CPC分类号： G01N33/6896 ,  A01K2217/05 ,  A61K38/1709 ,  C07K1/22 ,  C07K14/47 ,  C07K14/4713 ,  C07K16/18 ,  C12Q1/6883 ,  C12Q2600/156 ,  G01N33/564 ,  G01N33/57484 ,  G01N33/6893 ,  G01N2800/285

摘要： Described is a method for diagnosing a person having multiple sclerosis (MS) or being at risk of developing MS, comprising the following steps: providing a sample of a body fluid or tissue from said person, said sample containing at least one of the wild type SCF-Apoptosis-Response Gene- (wt-SARG-1-) protein and nucleic acids encoding wt-SARG-1, if taken from a person not having MS or a risk of aquiring MS, detecting the presence of wt-SARG-1-protein or nucleic acids encoding wt-SARG-1 in said sample and diagnosing MS or a risk of aquiring MS, if wt-SARG-1-protein or nucleic acids encoding wt-SARG-1 are not present in said sample.

摘要翻译： 描述了用于诊断具有多发性硬化症（MS）或处于发展MS风险中的人的方法，包括以下步骤：从所述人提供体液或组织的样品，所述样品含有至少一种野生型 SCF-细胞凋亡 - 应答基因 - （wt-SARG-1-）蛋白和编码wt-SARG-1的核酸，如果取自不具有MS或没有MS的风险的人，则检测wt-SARG-1的存在 - 如果wt-SARG-1蛋白或编码wt-SARG-1的核酸不存在于所述样品中，则在所述样品中编码wt-SARG-1的蛋白质或核酸，并诊断MS或获得MS的风险。